Enliven Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, everyone. My name is Maury Raycroft. I am one of the biotech analysts at Jefferies. I would like to welcome the Enliven management team. We have Rick Fair, the CEO, and Ben Hohl, the CFO. Thanks so much for joining us today.
Thank you, Maury. We will do a fireside chat format.
Maybe for those who are new to the story, if you can give a one-minute intro to the company.
Sure. Thanks, Maury and the Jefferies team, for having us. We appreciate being here. Enliven is a company that focuses on developing better molecules against known biology. Our lead program is relcobatinib, or ELVN-001, which is a BCR-ABL1 TKI being developed in CML. We are initiating our first phase III trial in second-line plus CML patients imminently. Committed to starting that study before year-end, and it is November 17th by last count, so we are right on top of it. We have a pipeline asset in Graves' disease. We expect to be able to communicate more about that as we get closer to IND in 2027.
Got it. Yeah, that's a great intro. You mentioned the phase III study, which was the first question I was going to ask about. We're not seeing anything posted on ct.gov yet for the study. Can you say how far along you are with site selection and contracting, and when do you expect the first sites to be activated?
I can say we have sites activated, and the posting should be on ClinicalTrials.gov. If it's not, that's surprising and news. I'll need to follow up on that. We have identified approximately 180 sites globally for the study. We are in the process of contracting and going through IRB reviews in those sites and expect to have all of them activated at some point in 2027, but we'll start trial accrual imminently. Expect about an 18-month trial accrual based on what we're hearing from sites and triangulating with other CML studies, such that we could have a top-line readout as early as early 2029.
Got it. So for starting the study, I guess, it sounds like you're pretty far along with the process already. Starting the study would be dosing that first patient. Is that how you look at it, or?
Yeah, I would say screening and dosing, yeah.
Yeah. Okay. You mentioned the 18 months timeline to enroll. In the past, you've also said about 90 sites potentially. Wondering if that's still the case, and how many sites you think you would need to- Yeah.
We have about 180 sites globally.
Okay. About 2x that. Okay.
Expect to have those open at various times based on various health authority timelines, but by the second half of 2027, have all of those on board.
Got it. Okay. For enrollment by geographic region, I guess, how many patients do you anticipate could come from the U.S. versus ex-U.S.?
Yeah, I wouldn't try to forecast that now, but I would say, just based on site selection, a quarter to a third in the U.S., majority, more than half in Europe, and then the remainder coming out of Asian countries, including Japan, South Korea, Taiwan, Singapore.
Got it. Okay. For the phase III, the control arm is investigator choice. What are your latest expectations on MMR rates that you're assuming at weeks 24 and 96 for the control arm? How much additional MMR improvement do you expect for relcobatinib versus the second-gen TKIs over that period?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
